In February 2026, the University of Miami in the United States and the University of Tours in France published a study in Nature Communications, stating that nanobodies extracted from alpacas demonstrated rapid, long-lasting, and stable antidepressant effects in a mouse model of stress-induced depression. These nanobodies also show potential for combating various diseases. Currently, major pharmaceutical companies are investing heavily in developing a new generation of nanobody drugs to treat challenging conditions such as cancer, neuralgia, and chronic skin diseases, paving new pathways for precision medicine.
